-
Mashup Score: 3
“There’s no evidence that it happens, nor is there any mechanistic reason to imagine that it would happen,” Dr. Anthony Fauci said.
Source: NBC NewsCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 3
– Regular Approval Based on Overall Survival Results from Confirmatory EV-301 Trial – – First and Only FDA-Approved Therapy for Urothelial Cancer Patients Who Are Cisplatin-Ineligible and Have Previously Received One or More Prior Therapies, Based on Cohort 2 of Pivotal EV-201 Trial – Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.,…
Source: investor.seagen.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Thrilled to see EV approved for cis-ineligible patients after first line PD-1/L1. https://t.co/3HmgpI5Gty
-
-
Mashup Score: 6
Standard treatment for high-risk non-muscle-invasive bladder cancer is transurethral resection of bladder tumour followed by intravesical BCG immunoth…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Thrilled to finally share in peer-reviewed form: KN057 Pembrolizumab in BCG Unresponsive CIS. The first of hopefully many effective non-surgical options ahead for this disease, much work still yet to do. @UroDocAsh @PGrivasMDPhD @joostboormans https://t.co/LNJNymXcfg
-
-
Mashup Score: 0
Locally advanced or metastatic urothelial carcinoma is generally incurable and has scarce treatment options, especially for cisplatin-ineligible patie…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
EV after PD-1/L1 in cis-ineligible pts w Advanced UC now in print. 52% ORR, 20% CR rate and mDoR 10.9 months...EV inching closer and closer to first line, where it likely belongs... AddThis | Home https://t.co/2oM2EiPMPo
-
-
Mashup Score: 11
Read about why Jae Park joined his colleagues at MSK and New York-Presbyterian to publicly show a united stance against hate.
Categories: Hem/Oncs, Latest HeadlinesTweet-
RT @DrMvandenBrink: ‘I Have to Be Hopeful’: Jae Park and MSK Community Unite against Asian Hate https://t.co/QyBKKO8yvW
-
RT @DrMvandenBrink: ‘I Have to Be Hopeful’: Jae Park and MSK Community Unite against Asian Hate https://t.co/QyBKKO8yvW
-
-
Mashup Score: 1FDA grants accelerated approval for sacituzumab govitecan - 4 year(s) ago
FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer.
Categories: Hem/Oncs, Latest HeadlinesTweet-
https://t.co/ceYqLcSleZ
-
-
Mashup Score: 0Virtual Communities of Oncology Practice: Optimizing Use of Immunotherapy-Based Treatment Regimens in Bladder Cancer - 4 year(s) ago
Log In Log in Forgot your password? Create Account We will not share your email with anyone. Password must be at least 8 characters. Show or Hide the password you are typing. Please indicate that you accept the privacy policy and terms of service I have read and accept the Privacy…
Categories: Hem/Oncs, Latest HeadlinesTweet-
Join me and #DrPeterO'Donnell from the @UCCancerCenter as we discuss complex cases in advanced UC. Continue the conversation on bladder cancer through @gotoPER's online discussion board. Sign up to get started: https://t.co/x30PIJ8PMP https://t.co/cw6VSEs1fh
-
-
Mashup Score: 3
The in-depth interview covers the data that led to the NMIBC approval, outlines the appropriate patient population for pembrolizumab, and reviews side-effect management with the immune checkpoint inhibitor.
Source: Urology TimesCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @UrologyTimes: Dr. Arjun Balar discusses pembrolizumab in BCG-unresponsive NMIBC https://t.co/JH9O9eRH1g #urology #urologist #NMIBC #bla…
-
-
Mashup Score: 1IC-ONC | IC-ONC Ask the Experts - 5 year(s) ago
IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education. Founding Support through Educational Grants from Bristol-Myers Squibb.
Source: ic-onc.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @IC_ONC: Do you have an immuno-oncology question? @IC_ONC Ask the Experts https://t.co/7ipFFUpLR4 .@VamsiVelcheti .@ArjunBalarMD .@MLG_…
-
-
Mashup Score: 0
/PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq: SGEN) today announced positive…
Source: www.prnewswire.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Truly impressive data for EV after progression on PD-1/L1 in cis-ineligible patients and lends further optimism for the combination. Single-arm studies have fooled us before but I’m cautiously optimistic. https://t.co/V2Azt7LBXY
-
RT @marklewismd: Pac vs Biggie Drake vs Pusha T Nicki vs Tony I AM HERE FOR THIS RAP BATTLE https://t.co/HWTHYRJfs0